Tuesday 1st May 2018
A quick look at 7 medications to treat Pulmonary Hypertension
Pulmonary hypertension is raised blood pressure within the pulmonary arteries, which are the blood vessels that supply the lungs.
Tuesday 1st May 2018
Pulmonary hypertension is raised blood pressure within the pulmonary arteries, which are the blood vessels that supply the lungs.
Tuesday 30th May 2017
For this month's blog excerpt I wanted to include some of my poetry from over the years and decided to show one I've written about the pain, physical and mental.
Tuesday 16th May 2017
We at SRUK have been working towards becoming members of the Association of Medical Research Charities (AMRC) over the past year and are pleased to announce that our application was accepted at the end of April. This is a great achievement for the charity, as membership is the hallmark of quality research funding and considerably increases the value of grants that we award.
Friday 12th May 2017
Organ involvement occurs later in people with diffuse scleroderma and anticentromere antibodies (ACAs).
Thursday 11th May 2017
Evidence suggests drugs in scleroderma trials have beneficial effects on skin, lung function and the heart.
Tuesday 9th May 2017
Friday 5th May 2017
We're calling for a clear commitment from the government to review and reform the medical exemption criteria for prescription charges, which was compiled in 1968 and will be 50 years old next year, to include all those with long-term conditions.
Wednesday 3rd May 2017
EULAR 2017 - Annual European Congress of Rheumatology in Madrid
Wednesday 3rd May 2017
There is a link between long-term physical health conditions, such as Raynaud’s phenomenon and scleroderma, and mental health problems such as depression, is well known. According to the Department of Health, more than 15 million people in England – 30% of the population – have one or more long-term conditions,1 and evidence suggests at least 30% of people with a long-term physical health condition also have a mental health condition.2 If you are struggling, you are therefore not alone.
Thursday 26th May 2016
Cytori Therapeutics Inc. announces that its US FDA-approved phase III STAR trial has enrolled its 80th patient (100% of target enrolment). All 80 patients enrolled thus far in both trial arms have been successfully treated without complications. Full trial data are expected to be available in mid-2017.